Oxaliplatin Injection Suppliers & Bulk Manufacturers
Available Forms: Solution for Injection
Available Strengths: 50 mg/10 mL, 100 mg/20 mL, 200 mg/40 mL
Reference Brands: Eloxatin(US & EU)
Category:
Oncology Cancer Care
Oxaliplatin Injection (50 mg, 100 mg, 200 mg) is a platinum-based chemotherapy drug used in the treatment of colorectal cancer. Administered via IV infusion, it is a key component of the FOLFOX regimen and widely used in both the U.S. and EU. Oxaliplatin disrupts DNA replication in cancer cells, making it essential in modern oncology treatment protocols.
Oxaliplatin Injection is available in Solution for Injection
and strengths such as 50 mg/10 mL, 100 mg/20 mL, 200 mg/40 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Oxaliplatin Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Oxaliplatin Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Oxaliplatin Injection is a platinum-based chemotherapeutic agent available in 50 mg, 100 mg, and 200 mg strengths for IV infusion. Widely used in the U.S. and EU, it is a key component of the FOLFOX regimen for the treatment of advanced and metastatic colorectal cancer. Oxaliplatin interferes with DNA replication, leading to cancer cell death. Approved for both adjuvant and palliative therapy, it plays a vital role in oncology B2B distribution. Available as a solution for infusion, Oxaliplatin supports effective cancer management and enhances treatment outcomes for colorectal cancer patients across global markets
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing